Supercharged immune cells take on Hard-to-Treat prostate cancer
NCT ID NCT03873805
First seen Jun 09, 2026 · Last updated Jun 19, 2026 · Updated 4 times
Summary
This early-phase trial tests a new type of immunotherapy called PSCA-CAR T cells in 14 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to standard hormone therapy. The treatment involves taking a patient's own immune cells, engineering them in a lab to recognize and attack prostate cancer cells, and infusing them back along with a low dose of chemotherapy. The main goals are to find the safest dose and to watch for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PSCA-targeting CAR-T cells (engineered immune cells) and cyclophosphamide (chemotherapy)
What this could lead to
If it works, this could point toward a new treatment option for advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong
This is a very early, small phase 1 trial focused on safety, not effectiveness. The treatment may cause severe side effects like cytokine release syndrome, and it may not shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.